Abstract
Background: MicroRNA-19b (miR-19b) is essential in determining oligodendroglia proliferation. Phosphatase and tensin homologue on chromosome 10 (PTEN) is considered the target of miR-19b and participates in oligodendrocyte differentiation and proliferation.
Methods: Murine EAE was induced by myelin oligodendrocyte glycoprotein (MOG35– 55). For EAE reversal, artificially synthesized agomiR-19b was intravenous injected after immunization.
Results: We found that the expression of miR-19b is significantly reduced in an experimental autoimmune encephalomyelitis (EAE) mouse model. This downregulation, which is associated with the neurological scores, can be dramatically ameliorated by agomiR-19b. Our results show that agomiR-19b increases the expression of myelin basic protein (MBP) and cyclic nucleotide phosphodiesterase (CNP), which are regularly utilized as molecular markers of oligodendrocytes. Furthermore, our study also revealed that miR-19b probably affects the expression of PTEN in the EAE model.
Conclusion: These results indicate that the restoration of miR-19b probably exerts its therapeutic effect by affecting PTEN in the pathogenesis of EAE.
Keywords: MiR-19b, experimental autoimmune encephalomyelitis, oligodendrocyte, PTEN, agomiR-19b, MBP, CNP.
Current Molecular Medicine
Title:MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis
Volume: 18 Issue: 5
Author(s): B. Hu, Z.L. Hu, Q.M. Zeng, B. Xiao and H. Yang*
Affiliation:
- Department of Neurology, Xiangya Hospital of Central South University, Changsha, 410008,China
Keywords: MiR-19b, experimental autoimmune encephalomyelitis, oligodendrocyte, PTEN, agomiR-19b, MBP, CNP.
Abstract: Background: MicroRNA-19b (miR-19b) is essential in determining oligodendroglia proliferation. Phosphatase and tensin homologue on chromosome 10 (PTEN) is considered the target of miR-19b and participates in oligodendrocyte differentiation and proliferation.
Methods: Murine EAE was induced by myelin oligodendrocyte glycoprotein (MOG35– 55). For EAE reversal, artificially synthesized agomiR-19b was intravenous injected after immunization.
Results: We found that the expression of miR-19b is significantly reduced in an experimental autoimmune encephalomyelitis (EAE) mouse model. This downregulation, which is associated with the neurological scores, can be dramatically ameliorated by agomiR-19b. Our results show that agomiR-19b increases the expression of myelin basic protein (MBP) and cyclic nucleotide phosphodiesterase (CNP), which are regularly utilized as molecular markers of oligodendrocytes. Furthermore, our study also revealed that miR-19b probably affects the expression of PTEN in the EAE model.
Conclusion: These results indicate that the restoration of miR-19b probably exerts its therapeutic effect by affecting PTEN in the pathogenesis of EAE.
Export Options
About this article
Cite this article as:
Hu B. , Hu Z.L., Zeng Q.M., Xiao B. and Yang H. *, MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004123716
DOI https://dx.doi.org/10.2174/1566524018666181004123716 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Mesenchymal Stromal Cell Secretome: Immunomodulation, Tissue Repair and Effects on Neurodegenerative Conditions
Current Stem Cell Research & Therapy Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Reciprocity in Microbiome and Immune System Interactions and its Implications in Disease and Health
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Controlling Autoimmunity by Modulating the Function of Autoantigen-Specific T Cells (Guest Editor: Andrew D. Weinberg)]
Current Drug Targets - Inflammation & Allergy Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?
Current Molecular Medicine Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Physiology and Therapeutic Potential of the Thymic Peptide Thymulin
Current Pharmaceutical Design